These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36555243)

  • 1. Comprehensive Analysis of FASN in Tumor Immune Infiltration and Prognostic Value for Immunotherapy and Promoter DNA Methylation.
    Zhang M; Yu L; Sun Y; Hao L; Bai J; Yuan X; Wu R; Hong M; Liu P; Duan X; Wang C
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer.
    Xiong Q; Feng D; Wang Z; Ying Y; Xu C; Wei Q; Zeng S; Yang L
    Front Immunol; 2022; 13():836939. PubMed ID: 35392075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
    Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
    Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
    Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
    Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of
    Liu J; Zhu B; Chen J; Cao Y
    Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer analysis of Homeobox B9 as a predictor for prognosis and immunotherapy in human tumors.
    Jin Q; Xu L; Wang J; Lin J; Lin H
    Aging (Albany NY); 2023 Jun; 15(11):5096-5124. PubMed ID: 37301547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
    Mo Z; Li P; Cao Z; Zhang S
    Front Immunol; 2021; 12():564948. PubMed ID: 34290693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
    Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
    Front Immunol; 2022; 13():951247. PubMed ID: 35935945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive landscape of the miRNA-regulated prognostic marker LAYN with immune infiltration and stemness in pan-cancer.
    Jiawen W; Jinfu W; Jianyong L; Yaoguang Z; Jianye W
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):10989-11011. PubMed ID: 37335337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancancer Analysis of Revealed
    Cui J; Tian Y; Liu T; Lin X; Li L; Li Z; Shen L
    Dis Markers; 2022; 2022():5447017. PubMed ID: 36118672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic Gene Sets Reveal Features of the Tumor Immune Microenvironment and Predict Prognosis and Immunotherapy Response: A Pan-Cancer Analysis.
    Pan H; Pan J; Li P; Wu J
    Front Immunol; 2022; 13():858246. PubMed ID: 35493519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of EphA2 in pan-cancer: A prognostic biomarker associated with cancer immunity.
    Li Y; Fei H; Xiao Z; Lu X; Zhang H; Liu M
    Clin Exp Pharmacol Physiol; 2024 Aug; 51(8):e13902. PubMed ID: 38886133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-genomic Features of Prostate Cancer.
    Dairo O; DePaula Oliveira L; Schaffer E; Vidotto T; Mendes AA; Lu J; Huynh SV; Hicks J; Sowalsky AG; De Marzo AM; Joshu CE; Hanratty B; Sfanos KS; Isaacs WB; Haffner MC; Lotan TL
    Cancer Res Commun; 2024 Jan; 4(1):152-163. PubMed ID: 38112617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.